Research programme: HIV vaccine - Novavax/US Universities

Drug Profile

Research programme: HIV vaccine - Novavax/US Universities

Alternative Names: HIV VLP vaccine - Novavax

Latest Information Update: 02 May 2012

Price : $50

At a glance

  • Originator Duke University; Emory University; Harvard Medical School; Novavax; University of Alabama
  • Developer Novavax
  • Class AIDS vaccines; Virus-like particle vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported HIV infections

Most Recent Events

  • 02 May 2012 No development reported - Preclinical for HIV infections in USA (unspecified route)
  • 19 Dec 2008 Preclinical development is ongoing
  • 22 Jan 2007 Preclinical development is ongoing
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top